Trial
NCT01982253
Fasiglifam 25 mg BID vs 50 mg QD
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Takeda
Collaborators
—
Condition
Type 2 Diabetes Mellitus
Intervention
Fasiglifam
Why stopped
Due to potential concerns about liver safety (See Detailed Description)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-07